Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
PaperCitations, authors & open-access status
Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 104 citations, 2019 year and closed oa status.
104
Citations
2019
Year
closed
OA Status